Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

Gaudinski Martin R.; Houser Katherine V.; Morabito Kaitlyn M.; Hu Zonghui; Yamshchikov Galina; Rothwell Ro Shauna; Berkowitz Nina; Mendoza Floreliz; Saunders Jamie G.; Novik Laura; Hendel Cynthia S.; Holman LaSonji A.; Gordon Ingelise J.; Cox Josephine H.; Edupuganti Srilatha; McArthur Monica A.; Rouphael Nadine G.; Lyke Kirsten E.; Cummings Ginny E.; Sitar Sandra; Bailer Robert T.; Foreman Bryant M.; Burgomaster Katherine; Pelc Rebecca S.; Gordon David N.; DeMaso Christina R.; Dowd Kimberly A.; Laurencot Carolyn; Schwartz Richard M.; Mascola John R.; Graham Barney S.; Pierson Theodore C.; Ledgerwood Julie E.; Chen Grace L.

首页> 外文期刊>The Lancet >Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

【24h】

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

机译：两种Zika病毒DNA疫苗候选的安全性，耐受性和免疫原性在健康成人中：随机，开放标签，第1期临床试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background The Zika virus epidemic and associated congenital infections have prompted rapid vaccine development. We assessed two new DNA vaccines expressing premembrane and envelope Zika virus structural proteins.

机译：背景技术Zika病毒流行病和相关的先天性感染促使快速疫苗发育。我们评估了两种表达前一种新的DNA疫苗，表达前膜和包膜Zika病毒结构蛋白。

著录项

来源
《The Lancet》 |2018年第10120期|共11页
作者
Gaudinski Martin R.; Houser Katherine V.; Morabito Kaitlyn M.; Hu Zonghui; Yamshchikov Galina; Rothwell Ro Shauna; Berkowitz Nina; Mendoza Floreliz; Saunders Jamie G.; Novik Laura; Hendel Cynthia S.; Holman LaSonji A.; Gordon Ingelise J.; Cox Josephine H.; Edupuganti Srilatha; McArthur Monica A.; Rouphael Nadine G.; Lyke Kirsten E.; Cummings Ginny E.; Sitar Sandra; Bailer Robert T.; Foreman Bryant M.; Burgomaster Katherine; Pelc Rebecca S.; Gordon David N.; DeMaso Christina R.; Dowd Kimberly A.; Laurencot Carolyn; Schwartz Richard M.; Mascola John R.; Graham Barney S.; Pierson Theodore C.; Ledgerwood Julie E.; Chen Grace L.;
展开▼
作者单位

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Biostat Res Branch Div Clin Res NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

Emory Sch Med Emory Vaccine Ctr Dept Med Div Infect Dis Hope Clin Decatur GA USA;

Univ Maryland Sch Med Ctr Vaccine Dev Baltimore MD 21201 USA;

Emory Sch Med Emory Vaccine Ctr Dept Med Div Infect Dis Hope Clin Decatur GA USA;

Univ Maryland Sch Med Ctr Vaccine Dev Baltimore MD 21201 USA;

Univ Maryland Sch Med Ctr Vaccine Dev Baltimore MD 21201 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Viral Pathogenesis Sect NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Viral Pathogenesis Sect NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Viral Pathogenesis Sect NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Viral Pathogenesis Sect NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Viral Pathogenesis Sect NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Viral Pathogenesis Sect NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Viral Pathogenesis Sect NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr NIH 9000 Rockville Pike Bethesda MD 20892 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials [J] . Gaudinski Martin R., Houser Katherine V., Morabito Kaitlyn M., The Lancet . 2018,第10120期

机译：两种Zika病毒DNA疫苗候选的安全性，耐受性和免疫原性在健康成人中：随机，开放标签，第1期临床试验
2. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials (vol 391, pg 563, 2018) [J] . Modjarrad Kayvon, Lin Leyi, George Sarah L., The Lancet . 2020,第10241期

机译：纯净的含有纯化的Zika病毒疫苗候选的三次试验的初步综合安全性和免疫原性结果：第1阶段，随机，双盲，安慰剂对照临床试验（Vol 391，PG 563,2018）
3. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials [J] . Modjarrad Kayvon, Lin Leyi, George Sarah L., The Lancet . 2018,第10120期

机译：纯净的综合安全性和免疫原性结果由纯化的止动Zika病毒疫苗候选的三次试验结果：第1阶段，随机，双盲，安慰剂对照临床试验
4. A double-blind, randomized phase II trial of thesafety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults [C] . Shelly A. McNeil, Scott A. Halperin, Joanne M. Langley, Lancefield International Symposium on Streptococci and Streptococcal Diseases . 2006

机译：一种双盲，随机期II试验，对健康成人的26岁的26岁群体的疫苗疫苗
5. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
6. Safety tolerability and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised open-label phase 1 clinical trials [O] . Martin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, -1

机译：健康成人中两种Zika病毒DNA疫苗候选者的安全性耐受性和免疫原性：随机开放标签1期临床试验
7. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial [O] . Zhiwei Wu, Yaling Hu, Miao Xu, 2021

机译：60岁及以上健康成人的灭活SARS-COV-2疫苗（Coronavac）的安全性，耐受性和免疫原性：随机，双盲，安慰剂控制，第1/2期临床试验

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

摘要

著录项

相似文献

相关主题

期刊订阅